Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2016
May 2016, Vol 7, No 4
May 2016, Vol 7, No 4
Secondary Pathology Review May Improve Clinical Outcomes
By
Meg Barbor, MPH
Quality Care
,
Policies & Guidelines
May 2016, Vol 7, No 4
Secondary pathology review can significantly improve clinical outcomes through precise and accurate pathology diagnoses, according to Lavinia P. Middleton, MD, Professor, Department of Pathology, M.D. Anderson Cancer Center, Houston, TX.
Read Article
Web-Based Reporting Beneficial in Tracking Medication Occurrence
By
Meg Barbor, MPH
Quality Care
,
Policies & Guidelines
May 2016, Vol 7, No 4
Web-based reporting in the outpatient community setting is not only feasible, but it can identify areas that need quality improvement initiatives, according to J. Russell Hoverman, MD, PhD, Vice President of Quality Programs, Texas Oncology, PA, Dallas.
Read Article
Pembrolizumab Elicits High Response in Merkel-Cell Carcinoma
By
Wayne Kuznar
AACR Meeting Highlights
May 2016, Vol 7, No 4
Read Article
Cost of Surgery Comparable to Nonsurgical Options in Advanced-Stage Oropharynx Cancer
By
Meg Barbor, MPH
Value in Oncology
May 2016, Vol 7, No 4
Surgery for the primary treatment of T1-T3 oropharynx squamous-cell carcinoma (OPC) does not increase the cost of care, even for patients requiring adjuvant treatment, according to A. Daniel Pinheiro, MD, an otolaryngologist at Mercy Clinic Ear, Nose, and Throat-Surgery Center, Springfield, MO, who presented his findings at the 2016 Multidisciplinary Head and Neck Cancer Symposium.
Read Article
Adverse Events Associated with Tyrosine Kinase Inhibitors Carry High Economic Burden
By
Chase Doyle
Value in Oncology
May 2016, Vol 7, No 4
A study using the FDA Adverse Event Reporting System (FAERS) has demonstrated the high cost burden of adverse events (AEs) associated with the use of tyrosine kinase inhibitors (TKIs) in patients with chronic myelogenous leukemia (CML). The results were presented at ASH 2015 by Nicola Wallis, MRCPath, FFPM, Bristol-Myers Squibb, Princeton, NJ.
Read Article
OPT-IN Pilot Project Increases Clinician Understanding of Treatment Prices
By
Meg Barbor, MPH
Value in Oncology
May 2016, Vol 7, No 4
Read Article
Genomic Instability Score Predicts Survival in Patients with Ovarian Cancer
NCCN Conference Highlights
May 2016, Vol 7, No 4
A higher score on a composite index of homologous recombination deficiency (HRD), indicating genomic instability, correlated with improved progression-free survival (PFS) and overall survival (OS) in patients with ovarian cancer who have received platinum-containing chemotherapy, according to results presented at the 2016 Society of Gynecologic Oncology annual meeting.
Read Article
NCCN Evidence Blocks Help Frame Value-Based Decisions for Systemic Therapies
By
Wayne Kuznar
NCCN Conference Highlights
May 2016, Vol 7, No 4
The evidence blocks were incorporated into the National Comprehensive Cancer Network (NCCN) clinical practice guidelines late last year and act as a visual representation of 5 key measures related to specific recommendations.
Read Article
Immunotherapy Takes Center Stage in the Updated NCCN Guideline for Advanced Melanoma
By
Wayne Kuznar
NCCN Conference Highlights
May 2016, Vol 7, No 4
The updated National Comprehensive Cancer Network (NCCN) guideline (version 2.2016) for the management of advanced melanoma reflects the increasing role of immune checkpoint inhibitors and targeted agents, as more data establish their superior efficacy over traditional chemotherapy.
Read Article
Updated NCCN Multiple Myeloma Guideline Expands Patient Eligibility and Therapeutic Options
By
Wayne Kuznar
NCCN Conference Highlights
May 2016, Vol 7, No 4
The population of patients with multiple myeloma who are eligible for therapy has been expanded to include asymptomatic patients with certain features, according to the most recent National Comprehensive Cancer Network (NCCN) guideline (version 3.2016).
Read Article
Page 2 of 3
1
2
3
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
3.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma